EPP Dynamic Talks – Lifesciences (May 18-27, 2021)

Alan Crowther

Alan Crowther is the President of Global Markets of Eversana, responsible for overseeing the Global Pricing solutions for Alliance. He brings 20 years of leadership, consulting and technology experience with him to the position. Alan has previously held roles as CEO at Alliance; founder of Adjility Health, a firm
focused on life sciences analytical
software; Vice President at Capgemini; Co-founder and Officer
at Adjoined Consulting, where
he ran the Life Sciences practice
and was part of the leadership of the venture-backed company and helped drive it to a successful
$200MM+ exit. Prior to Adjoined, Mr. Crowther was head of services for a small software company
that exited to BEA Systems; and was a manager at Andersen Consulting (Accenture) before that.
He is a graduate of Princeton University.

Axel Boehnke

He´s fully responsible for all market access aspects, Pricing and Reimbursement-issues, Health Technology Assessment, accelerated patient access, early evidence planning, and institutional interactions, focusing on orphan diseases and Gene Therapy. Before, Axel was a Director Market Access at MorphoSys AG, focusing on oncology and especially r/r DLBCL. He has in-depth knowledge and expertise in the specialized business, like Oncology, Autoimmune Diseases, (Ultra) Orphan Diseases, Hepatology, Anti-virals, etc. He also has in track record experience in therapeutic mass markets like cardiovascular or osteoporosis, with respective payer-interactions and contracting.
Axel started with Humira at Abbott in national responsibility, headed the Department of Market Access, managed Care at Servier, and served for experience in the biopharmaceutical industry for the last years. He is a Health Economist (University of Cologne) by education and holds a master’s degree in health and medical management (University Erlangen-Nurnberg). Axel is a member of the German Society of Market Access, the German Society of Health Economics, and the EU Market Access & Value Committee at ARM (Alliance for Regenerative Medicine). He published various articles on Benefit Assessment, Market Access, Healthcare-System Issues, Disease Awareness (i.e. in Rheumatoid Arthritis or Psoriasis), and on Claims-Data-Analysis with Real World Evidence.

Richard Rahul

Richard Rahul is a Senior Manager in Monitor Deloitte. His core focus is on Life Sciences (Big pharma/medium pharma) and healthcare industries, besides health technology/digital health based firms. Richard’s expertise is in go-to market model optimization, innovative pricing models, value based selling, patient/customer experience design and operations, pricing and market access. He brings a global perspective having led and successfully executed engagements in the US, cross-EU and in China/India.

Libor Minichbauer

Libor is Director of Access and Pricing for Novartis Oncology. He currently covers markets in Asia, and MEA regions. He has 12 years of Pharma experience with roles in Market Access, Health Economics, and Development. Prior to joining the pharma industry he had spent several years in IT consulting, banking and finance. He holds B.S. and M.S. degrees in Finance and Marketing, IT, and Health Economics.

George Boretos

Andrew Stainthorpe

Andrew Stainthorpe has over 30 years of experience the health sector, 20 years in NHS health services research, 6 yrs with NICE leading evaluation programmes and 4 yrs as a market access consultant.

He provides advice to the pharmaceutical, diagnostic and medical device industries in developing approaches to achieve market access in the UK and Europe. He has also gained considerable experience of market access work in other markets in Europe (EU5 and Eastern Europe), the United States, Canada, LATAM, and APAC countries.

With NICE, he led the Interventional Procedures (IP) Programme working with industry and NHS to identify new procedures and devices/diagnostics which might benefit the service and patients. The role of the IP programme is to assess the value and rationale for the introduction of new approaches into the NHS through the production of NICE IP guidance. His leadership role involved liaison with manufacturers to identify and evaluate the evidence, acquisition of independent expert inputs and gaining wider clinical and academic opinion. With NICE he also set up and ran the Patient Access Schemes (PAS) Liaison Unit which involved developing (with manufacturers) and assessing (with the NHS) proposals to improve the value propositions for innovative technologies being assessed in the technology appraisal process. A key element of the role was to liaise with industry and work with them and the Department of Health to ensure the proposals:
• met the criteria set down in the Pharmaceutical Price Regulatory Scheme and
• were implementable in the NHS.

In NHS R&D he was Research Director for a large NHS trust, a role which involved all aspects of health services R&D. This included leading funding proposals and managing projects (including clinical trials and EU funded projects) through to analyzing the data and writing for publication. He has over 20 publications in peer reviewed journals, has presented at ISPOR and HTAi and many other conferences.

Oshik Komary

Oshik is the Director of Pricing for teva IM region. He currently covers markets in APAC, LATAM and MEA regions. He has 15 years of Pharma experience with roles in commercial, finance & operational excellence. Prior to joining the pharma industry, he had spent several years as a consultant in the US. He holds B.S. in Biotech Engineering and an MBA degree.

Ulf Staginnus

Ulf is SVP Global Market Access & Pricing at Ipsen since February 2018. He is a health economist and pharmaceutical industry executive with 25 years of international experience in the field of market access, pharmacoeconomics, pricing and reimbursement as well as health technology valuations within the biotechnology and pharmaceutical industry. He has a long track record in successfully developing launch pricing and patient access strategies for various innovative drugs across various disease areas such as oncology, cardiology, infectious diseases and orphan drugs within the top 10 pharmaceutical companies (Novartis Oncology, BMS, Pfizer, GSK Biologicals) and biotech start-ups (PTC Therapeutics, Endocyte Inc.).

The most recent industry positions prior to Ipsen have included VP, Market Access Shire Intl.; Head of Market Access Europe, PTC Therapeutics and Endocyte Inc.; Franchise Head, Oncology International Access and Reimbursement with Amgen Intl., all in Zug, Switzerland; Head of Pricing and Access, Novartis Oncology Europe, Milan, Italy and Barcelona, Spain.

Ulf graduated with an MA Economics – with a major focus on health economics – from the University of Bayreuth, Germany. During the course of his career, he also founded and run his own consultancy.

He is a regular speaker on access, pricing and health economics related matters and the co-author of “The Future of Health Economics”, published by Routledge, October 2016.

Todor Finkov

Todor is a senior consultant supporting the Global Pricing and Tender Management Practice in Zug-Switzerland, joining in 2018. His experience includes 15 years within Business Development, Commercial and Market Access in pharma companies such as Actavis, Allergan, Biogen, and various roles within health care administration in Bulgaria and USA. He’s responsible for leading and supporting projects as part of the Global Pricing and Tender Management Practice. He’s also an advisor to projects around pricing, contracting and tender management and market access. He holds an MBA in Healthcare Services Management from Johns Hopkins Carrey Business School., also a M.D. from Sofia Medical University in Bulgaria.

Sara Carvalho

IQVIA

Trevor Gunn

Trevor Gunn is Vice President- International Relations for Medtronic, the world’s largest medical technology company.
Trevor Gunn was formerly long-time Director of the Commerce Department’s Business Information Service for the Newly Independent States (BISNIS) the clearinghouse for US Government information for doing business in the former Soviet Union. He has served continuously for the past 28 years, and currently serves, as Adjunct Professor at CERES and the Landegger Program in International Business Diplomacy at the School of Foreign Service and Georgetown University. He is a Vicennial Silver Medalist.
He received his B.A. from University of San Francisco. He received his Ph.D. in International Relations from the London School of Economics in 1992.
He has worked with the Chamber of Commerce of Southern Sweden, Dover Elevator Corporation (now ThyssenKrupp of Germany), International Executive Service Corps and on the staffs of the former San Francisco Mayor and two U.S. Senators from California. He is the Founder and Chairman of the USA Healthcare Alliance (USAHA) . He sits on the U.S. State Department’s Stakeholder Advisory Board on the OECD Guidelines on Corporate Social Responsibility; is an official Advisor to the Office of the US Trade Representative (USTR) in the “Industry Trade Advisory” system of the US Government. Gunn chairs the International Affairs Committee at Medtech Europe, Europe's largest medical technology trade association. Further, he is a Member of the Board of Directors for the US-Russia Business Council. Gunn is Chair Emeritus and Board Member of the Executive Council on Diplomacy. He sits on the Board of the Washington Export Council(Washington, D.C.), the Board of Advisers of the Washington International Business Council. Finally, he serves on the Advisory Board of the University of Minnesota, Carlson Business School's, Carlson Global Institute.

Troy Fix

Troy Fix, Director, Commercial Tender Excellence at CSL Behring has over 21 years of experience in sales, sales management, marketing and global project delivery in the pharmaceutical, vaccine and biopharmaceutical industries. His current focus is leading the enablement of the Commercial Operations Tender business globally. Troy holds Bachelors and Master’s degrees from Minnesota State University, Mankato.

Nanxin (Nick) Li

Nanxin (Nick) Li, PhD, MBA is currently Global/US Market Access Lead at uniQure, a leading gene therapy company, where he leads the efforts to demonstrate the value of pipeline products and enable optimal patient access to these therapies. Nick is an experienced leader in integrating value and access into development and commercialization process, optimizing product value proposition throughout life cycle, and delivering reimbursement successes for innovative products. He has a solid track record of making impacts on business. Prior to uniQure, he led value and access HEOR efforts at Bioverativ, a Sanofi company, for the Rare Blood Disorder franchise, including global launch of the first extended half-life hemophilia products Eloctate and Alprolix. He has also worked on other major brands in multiple therapeutic areas, including hematology/oncology, rheumatology, cardiovascular, and metabolic diseases. Nick has been invited to speak on value and access of innovative therapies in many industry congresses and events in the US and EU.

Finn Ziegler

Catarina Lopes Pereira